FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single Agent for Squamous Cell Carcinoma of the Anal Canal By Ogkologos - June 20, 2025 453 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the POD1UM-303/InterAACT 2 and POD1UM-202 studies Source RELATED ARTICLESMORE FROM AUTHOR ESMO’s Special Consultative Status with United Nations Economic and Social Council (UN ECOSOC) Confirmed Until 2028 EMA Recommends Extension of Indications for Selumetinib ESMO Calls for Urgent Changes to the in Vitro Diagnostic Medical Devices Regulation (IVDR) in Order to Safeguard Cancer Research in Europe MOST POPULAR Olive Oil Found to Reduce Risk of Death from Dementia, Cancer,... January 13, 2022 ESMO Call for Stronger Cancer Prevention and Care Mirrored in WHO... July 4, 2025 Coffee Shop Owner Runs Competitor’s Business For Free After Hearing He... December 18, 2019 Utility of Genomic Profiling Use for Targeted Therapy in a Phase... May 6, 2025 Load more HOT NEWS First-Line Treatment with Atezolizumab Associated with Improved OS in Patients with... European Lung Cancer Congress 2024 2020 round-up: Our biggest cancer stories of the year ΝΕΥΡΟΕΝΔΟΚΡΙΝΕΙΣ ΟΓΚΟΙ (ΝΕΤS)
